Menu
Commercialized Inventions
iPS cell-derived cardiomyocyte products CarmyA
Inventor
Itsunari Minami and Norio Nakatsuji (Kyoto University)
Vendor
Myoridge Co., Ltd.
Description
1. Application to regenerative medicine products
A U.S. company is conducting preclinical studies of a regenerative medicine product for the treatment of chronic heart failure, using iPS cell-derived cardiomyocytes generated by this differentiation method.
Further, for companies developing regenerative medicine products, Myoridge provides support services for the development of culture medium and its manufacturing process.
2. Cardiomyocytes for drug evaluation
The use of drugs, such as anticancer drugs, antibacterial drugs, and analgesics, is sometimes restricted due to their side effects on the heart (cardiotoxicity), and the evaluation of these side effects is costly and time-consuming. The use of iPS cell-derived cardiomyocytes generated by this technology for such evaluation may solve the above problems, and verification experiments are being conducted by pharmaceutical manufacturers.
Have you found what you were looking for?
- Interested in a particular research activity
- Cannot find the information
- Have questions on how to utilize research results
Feel free to contact us and get answers to your questions.
Inquiry
3rd Floor, International Science
Innovation Building, Kyoto University
Yoshidahonmachi, Sakyo-ku, Kyoto
600-8501 JAPAN